Literature DB >> 6690407

Immune response to atypical mycobacteria: immunocompetence of heavily infected mice measured in vivo fails to substantiate immunosuppression data obtained in vitro.

I M Orme, F M Collins.   

Abstract

The results of in vitro experiments designed to measure the immunocompetence of mice heavily infected with the atypical mycobacterial pathogens Mycobacterium avium and Mycobacterium simiae were compared with the results of experiments which used in vivo approaches. Blastogenic responsiveness in vitro both to mitogen and to alloantigen was severely depressed in the heavily infected mice; this responsiveness could be restored by removal of an inhibitory Thy-1.2-, nylon wool-adherent cell population. No evidence was found to support the previous contention that suppressor T cells may play a role in the inhibition of this responsiveness. These results were then compared with experiments which measured the ability of the infected animal to elicit a delayed-type hypersensitivity response to sheep erythrocytes in vivo. However, although delayed-type hypersensitivity responses in vivo were also depressed, evidence was obtained which suggested that this unresponsiveness was due to inadequate sensitization of T cells, possibly due to catabolism of antigen, rather than due to the influence of an active, immunosuppressive mechanism. Finally, despite the severely depressed ability of cells from infected mice to respond to alloantigenic stimulation in vitro, infected animals were fully able to cause the regression of a tumor implant in vivo.

Entities:  

Mesh:

Year:  1984        PMID: 6690407      PMCID: PMC263383          DOI: 10.1128/iai.43.1.32-37.1984

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  21 in total

1.  Suppressor T-cells in BCG-infected mice.

Authors:  F M Collins; S R Watson
Journal:  Infect Immun       Date:  1979-08       Impact factor: 3.441

2.  Importance of thymus-derived lymphocytes in cell-mediated immunity to infection.

Authors:  R J North
Journal:  Cell Immunol       Date:  1973-04       Impact factor: 4.868

3.  A rapid method for the isolation of functional thymus-derived murine lymphocytes.

Authors:  M H Julius; E Simpson; L A Herzenberg
Journal:  Eur J Immunol       Date:  1973-10       Impact factor: 5.532

4.  Suppression of spleen natural killing activity induced by BCG.

Authors:  M Ito; P Ralph; M A Moore
Journal:  Clin Immunol Immunopathol       Date:  1980-05

5.  Activated macrophages kill tumour cells by releasing arginase.

Authors:  G A Currie
Journal:  Nature       Date:  1978-06-29       Impact factor: 49.962

6.  Development of suppressor T cells in mice heavily infected with mycobacteria.

Authors:  S R Watson; F M Collins
Journal:  Immunology       Date:  1980-03       Impact factor: 7.397

7.  Mechanisms of action of Mycobacterium bovis BCG-induced suppressor cells in mitogen-induced blastogenesis.

Authors:  R Turcotte; S Lemieux
Journal:  Infect Immun       Date:  1982-04       Impact factor: 3.441

8.  The specificity of suppressor T cells induced by chronic Mycobacterium avium infection in mice.

Authors:  S R Watson; F M Collins
Journal:  Clin Exp Immunol       Date:  1981-01       Impact factor: 4.330

9.  Evidence for two distinct populations of suppressor cells in the spleens of Mycobacterium bovis BCG-Sensitized mice.

Authors:  R Turcotte
Journal:  Infect Immun       Date:  1981-11       Impact factor: 3.441

10.  Protection against Mycobacterium tuberculosis infection by adoptive immunotherapy. Requirement for T cell-deficient recipients.

Authors:  I M Orme; F M Collins
Journal:  J Exp Med       Date:  1983-07-01       Impact factor: 14.307

View more
  19 in total

1.  Intramacrophage growth of Mycobacterium avium during infection of mice.

Authors:  C Frehel; C de Chastellier; C Offredo; P Berche
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

Review 2.  AIDS-related mycobacterial disease.

Authors:  F M Collins
Journal:  Springer Semin Immunopathol       Date:  1988

3.  Lymphoproliferative responses to mitogens and prepared antigens of M. avium complex in patients with HIV infection.

Authors:  R M Novak; J Koirala; M L Sirdar; N D'Alfonso-Laghi; L Moreira; D L Pitrak; M Ghassemi
Journal:  J Clin Immunol       Date:  2000-01       Impact factor: 8.317

4.  CD4+ T cells but Not CD8+ or gammadelta+ lymphocytes are required for host protection against Mycobacterium avium infection and dissemination through the intestinal route.

Authors:  Mary Petrofsky; Luiz E Bermudez
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

5.  T-helper 1-like subset selection in Mycobacterium bovis bacillus Calmette-Guérin-infected resistant and susceptible mice.

Authors:  I Kramnik; D Radzioch; E Skamene
Journal:  Immunology       Date:  1994-04       Impact factor: 7.397

6.  Dissemination of enteric Mycobacterium avium infections in mice rendered immunodeficient by thymectomy and CD4 depletion or by prior infection with murine AIDS retroviruses.

Authors:  I M Orme; S K Furney; A D Roberts
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

7.  Interleukin-12-stimulated natural killer cells can activate human macrophages to inhibit growth of Mycobacterium avium.

Authors:  L E Bermudez; M Wu; L S Young
Journal:  Infect Immun       Date:  1995-10       Impact factor: 3.441

Review 8.  The Mycobacterium avium complex.

Authors:  C B Inderlied; C A Kemper; L E Bermudez
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

9.  Impairment of lymphocyte proliferative responses and interleukin-2 production in susceptible (C57BL/6) mice infected with Salmonella typhimurium.

Authors:  M Deschenes; M Guenounou; E Ronco; F Vacheron; C Nauciel
Journal:  Immunology       Date:  1986-06       Impact factor: 7.397

10.  Visceral leishmaniasis in congenic mice of susceptible and resistant phenotypes: immunosuppression by adherent spleen cells.

Authors:  A D Nickol; P F Bonventre
Journal:  Infect Immun       Date:  1985-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.